SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Cyclacel Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
23254L405
(CUSIP Number)
August 12, 2016
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
o
|
Rule 13d-1(b)
|
|
x
|
Rule 13d-1(c)
|
|
o
|
Rule 13d-1(d)
|
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 23254L405
|
13G
|
Page 2 of 8 Pages
|
|
1
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
TANG CAPITAL PARTNERS, LP
|
|
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
(a) o
(b) x
|
|
3
|
SEC USE ONLY
|
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON WITH
|
5
|
SOLE VOTING POWER
0
|
|
6
|
SHARED VOTING POWER
300,000
|
|
|
7
|
SOLE DISPOSITIVE POWER
0
|
|
|
8
|
SHARED DISPOSITIVE POWER
300,000
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
300,000
|
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
¨
|
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.6%
|
|
12
|
TYPE OF REPORTING PERSON
PN
|
|
CUSIP No. 23254L405
|
13G
|
Page 3 of 8 Pages
|
|
1
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
TANG CAPITAL MANAGEMENT, LLC
|
|
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
(a) o
(b) x
|
|
3
|
SEC USE ONLY
|
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON WITH
|
5
|
SOLE VOTING POWER
0
|
|
6
|
SHARED VOTING POWER
300,000
|
|
|
7
|
SOLE DISPOSITIVE POWER
0
|
|
|
8
|
SHARED DISPOSITIVE POWER
300,000
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
300,000
|
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
¨
|
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.6%
|
|
12
|
TYPE OF REPORTING PERSON
OO
|
|
CUSIP No. 23254L405
|
13G
|
Page 4 of 8 Pages
|
|
1
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
KEVIN C. TANG
|
|
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
(a) o
(b) x
|
|
3
|
SEC USE ONLY
|
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
UNITED STATES
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON WITH
|
5
|
SOLE VOTING POWER
0
|
|
6
|
SHARED VOTING POWER
300,000
|
|
|
7
|
SOLE DISPOSITIVE POWER
0
|
|
|
8
|
SHARED DISPOSITIVE POWER
300,000
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
300,000
|
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
¨
|
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.6%
|
|
12
|
TYPE OF REPORTING PERSON
IN
|
|
Item 1(a).
|
Name of Issuer:
|
Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”)
|
Item1(b).
|
Address of Issuer’s Principal Executive Offices:
|
200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey, 07922
|
Item 2(a).
|
Name of Person Filing:
|
This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin C. Tang, the manager of Tang Capital Management.
|
Item 2(b).
|
Address of Principal Business Office or, if none, Residence:
|
4747 Executive Drive, Suite 510, San Diego, CA 92121
|
Item 2(c).
|
Citizenship:
|
Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.
|
Item 2(d).
|
Title of Class of Securities:
|
Common Stock, par value $0.001 per share (the “Common Stock”)
|
Item 2(e).
|
CUSIP Number: 23254L405
|
|
Item 3.
|
Not applicable.
|
|
Item 4.
|
Ownership.
|
|
(a)
|
Amount Beneficially Owned:
|
Tang Capital Partners. Tang Capital Partners is the beneficial owner of 300,000 shares of the Issuer’s Common Stock.
Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin C. Tang.
Tang Capital Management. Tang Capital Management, as the general partner of Tang Capital Partners, may be deemed to beneficially own the shares of the Issuer’s Common Stock beneficially owned by Tang Capital Partners.
Kevin C. Tang. Kevin C. Tang, as manager of Tang Capital Management, may be deemed to beneficially own the shares of the Issuer’s Common Stock beneficially owned by Tang Capital Partners.
Mr. Tang disclaims beneficial ownership of all shares reported herein except to the extent of his pecuniary interest therein.
Page 5 of 8 pages
|
(b)
|
Percent of Class:
|
|
Tang Capital Partners
|
9.6%
|
|
Tang Capital Management
|
9.6%
|
|
Kevin C. Tang
|
9.6%
|
|
(c)
|
Number of shares as to which such person has:
|
|
(i)
|
sole power to vote or to direct the vote:
|
|
Tang Capital Partners
|
0 shares
|
|
Tang Capital Management
|
0 shares
|
|
Kevin C. Tang
|
0 shares
|
|
(ii)
|
shared power to vote or to direct the vote:
|
|
Tang Capital Partners
|
300,000 shares
|
|
Tang Capital Management
|
300,000 shares
|
|
Kevin C. Tang
|
300,000 shares
|
|
(iii)
|
sole power to dispose or to direct the disposition of:
|
|
Tang Capital Partners
|
0 shares
|
|
Tang Capital Management
|
0 shares
|
|
Kevin C. Tang
|
0 shares
|
|
(iv)
|
shared power to dispose or to direct the disposition of:
|
|
Tang Capital Partners
|
300,000 shares
|
|
Tang Capital Management
|
300,000 shares
|
|
Kevin C. Tang
|
300,000 shares
|
|
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨
|
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person.
|
Not applicable
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
|
Not applicable.
|
Item 8.
|
Identification and Classification of Members of the Group.
|
Not applicable.
|
Item 9.
|
Notice of Dissolution of Group.
|
Not applicable.
Page 6 of 8 pages
|
Item 10.
|
Certification.
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
Page 7 of 8 pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
Date:
|
August 19, 2016
|
||
|
TANG CAPITAL PARTNERS, LP
|
|||
|
By: Tang Capital Management, LLC, its General Partner
|
|||
|
By:
|
/s/ Kevin C. Tang
|
||
|
Kevin C. Tang, Manager
|
|||
|
TANG CAPITAL MANAGEMENT, LLC
|
|||
|
By:
|
/s/ Kevin C. Tang
|
||
|
Kevin C. Tang, Manager
|
|||
|
/s/ Kevin C. Tang
|
|||
|
Kevin C. Tang
|
|||
|
|
|||
Page 8 of 8 pages
Exhibit 99.1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of Cyclacel Pharmaceuticals, Inc. and further agree to the filing of this agreement as an exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.
|
Date: August 19, 2016
|
TANG CAPITAL PARTNERS, LP
|
|||
|
By:
|
Tang Capital Management, LLC
|
|||
|
Its:
|
General Partner
|
|||
|
By:
|
/s/ Kevin C. Tang
|
|||
|
Name:
|
Kevin C. Tang
|
|||
|
Title:
|
Manager
|
|||
|
TANG CAPITAL MANAGEMENT, LLC
|
||||
|
By:
|
/s/ Kevin C. Tang
|
|||
|
Name:
|
Kevin C. Tang
|
|||
|
Title:
|
Manager
|
|||
|
/s/ Kevin C. Tang
|
||||
|
Name:
|
Kevin C. Tang
|
|||